Verzenio (abemaciclib) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat advanced or metastatic breast cancer. Here are some key points about Verzenio:

Indications
- Type of Cancer: Advanced or metastatic breast cancer.
- Tumor Characteristics: Hormone receptor (HR)-positive and Show Full Answer

Verzenio (abemaciclib) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat advanced or metastatic breast cancer. Here are some key points about Verzenio:

Indications:
- Type of Cancer: Advanced or metastatic breast cancer.
- Tumor Characteristics: Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
- Usage:
- In combination with Faslodex (fulvestrant).
- As a stand-alone treatment (monotherapy) if tumors have progressed after endocrine therapy and chemotherapy.

Mechanism:
- Class: Kinase inhibitors.
- Function: Believed to work by slowing the growth of tumors.

Administration:
- Dosage: Taken twice daily with meals.
- Form: Tablet.

Side Effects:
- Common:
- Headache
- Fatigue
- Infections
- Blood cell changes
- Nausea
- Vomiting
- Loss of appetite
- Diarrhea
- Abdominal pain
- Serious:
- Severe diarrhea
- Lung disease
- Liver damage
- Venous thromboembolisms (blood clots in the veins)
- Harm to the fetus if taken by pregnant women

Additional Information:
- Hair Loss: Hair thinning and alopecia (hair loss) are common side effects but do not affect everyone.

For more details, you can visit the official Verzenio website: [Verzenio — Lilly USA](https://www.verzenio.com).

 This AI-generated response comes from MyBCTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Does Verzenio Cause Hair Loss? | MyBCTeam

Verzenio (Abemaciclib) for Breast Cancer | MyBCTeam